Today Genovis signed a distribution agreement with Innovative Biotech for exclusive rights to sell and market Genovis products in Singapore.

Singapore is an important emerging biotech-hub where the government is doing large investments for the country to become a major factor of power within Biotech and Life Science.

Through this latest distribution agreement Genovis is taking another important step in its expansion on the rapid growing Asian market. Genovis has earlier signed an agreement with a distributor for the Korean market.

Genovis offers new technological solutions in Transfection, RNAi, Imaging, and Antibody Engineering to customers who work with sophisticated research in pharmaceutical companies and within the academic research community. To provide customers with effective support and service Genovis market strategy is to choose partners with strong customer relations in strategic geographic markets.

In Europe Genovis has signed agreements with distributors for the Swedish, Danish, British, Irish, Spanish, Portuguese, Dutch, Belgian and German markets. In the United States Genovis works through its subsidiary Genovis Inc.

-Innovative Biotech continues to grow in the very important Life Science industry in Singapore. Therefore, this agreement means a lot for Genovis continuing expansion. Innovative Biotech is the perfect partner and has long experience of distribution with specialization in Genovis target areas such as antibody reagents and transfection technologies," says Sarah Fredriksson, CEO

Innovative Biotech Pte Ltd, incorporated in 1994, is a subsidiary of Rotary Engineering Limited, which is a public company listed on the Stock Exchange of Singapore. The company’s primary business is in the sales and marketing of medical, healthcare and biotechnology products to the research institution, universities, clinical lab, hospital and industrial clients.

-Our mission, 'Commitment to Excellence', is delivered through high quality products and unmatched service / application support. We are therefore extremely pleased to be able to work with Genovis, which has the latest and most advanced technology and completely unique products, sais Ragu Thina, Snr Vice President

About Us

Genovis’ business concept is to develop, produce and market innovative technologies that facilitate and enable development of new treatment methods and diagnostics for customers in the medical device and pharmaceutical industries. The Group consists of Genovis AB and the subsidiary GeccoDots AB. Genovis develops and sells unique enzymes (protein engineering portfolio) in innovative product formats that facilitate development and quality control of and biological drugs. GeccoDots uses nanotechnology to produce a new type of contrast agent that is used in medical imaging. Genovis shares are listed on NASDAQ OMX First North


Documents & Links